{
    "id": 26168,
    "fullName": "KAT6A - NCOA2",
    "impact": "fusion",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "KAT6A-NCOA2 (also referred to as MOZ-TIF2) results in the fusion of KAT6A-NCOA2, and leads to activation of downstream targets and transformation of cultured cells (PMID: 24446090, PMID: 26766589).",
            "references": [
                {
                    "id": 8310,
                    "pubMedId": 24446090,
                    "title": "The leucine twenty homeobox (LEUTX) gene, which lacks a histone acetyltransferase domain, is fused to KAT6A in therapy-related acute myeloid leukemia with t(8;19)(p11;q13).",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24446090"
                },
                {
                    "id": 8304,
                    "pubMedId": 26766589,
                    "title": "Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766589"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 7994,
        "geneSymbol": "KAT6A",
        "terms": [
            "KAT6A",
            "ARTHS",
            "MOZ",
            "MRD32",
            "MYST-3",
            "MYST3",
            "RUNXBP2",
            "ZC2HC6A",
            "ZNF220"
        ]
    },
    "variant": "KAT6A - NCOA2",
    "createDate": "03/22/2017",
    "updateDate": "03/22/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        {
            "gene": {
                "id": 10499,
                "geneSymbol": "NCOA2",
                "terms": [
                    "NCOA2",
                    "bHLHe75",
                    "GRIP1",
                    "KAT13C",
                    "NCoA-2",
                    "SRC2",
                    "TIF2"
                ]
            }
        }
    ],
    "evidence": [
        {
            "id": 10329,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with AMI-408 reduced growth of leukemia cells expressing KAT6A-NCOA2 (MOZ-TIF2) in culture, and decreased tumor burden and increased leukemia latency in xenograft models (PMID: 26766589).",
            "molecularProfile": {
                "id": 27357,
                "profileName": "KAT6A - NCOA2"
            },
            "therapy": {
                "id": 5463,
                "therapyName": "AMI-408",
                "synonyms": null
            },
            "indication": {
                "id": 1240,
                "name": "leukemia",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 8304,
                    "pubMedId": 26766589,
                    "title": "Targeting Aberrant Epigenetic Networks Mediated by PRMT1 and KDM4C in Acute Myeloid Leukemia.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26766589"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 27357,
            "profileName": "KAT6A - NCOA2",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}